Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
US Department of Justice
Healthtrust
Express Scripts
Federal Trade Commission
McKinsey
Dow
Cipla

Generated: May 24, 2018

DrugPatentWatch Database Preview

MAPROTILINE HYDROCHLORIDE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Maprotiline Hydrochloride patents expire, and when can generic versions of Maprotiline Hydrochloride launch?

Maprotiline Hydrochloride is a drug marketed by Am Therap, Mylan, Watson Labs, and Watson Labs Teva. and is included in ten NDAs.

The generic ingredient in MAPROTILINE HYDROCHLORIDE is maprotiline hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the maprotiline hydrochloride profile page.
Drug patent expirations by year for MAPROTILINE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for MAPROTILINE HYDROCHLORIDE
Synonyms for MAPROTILINE HYDROCHLORIDE
1-(3-Methylaminopropyl)dibenzo(b,e)bicyclo(2.2.2)octadiene hydrochloride
1-(3-methylaminopropyl)dibenzo[b,e]bicyclo[2.2.2]octadiene hydrochloride
1-(3-MethylaMinopropyl)dibenzo[b,e]bicyclo[2.2.2]octadienehydrochloride;1-(3-MethylaMinopropyl)dibenzo[b,e]bicyclo[2.2.2]octadienehydrochloride
10262-69-8 (Parent)
10347-81-6
3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine hydrochloride
347M816
7C8J54PVFI
9-(gamma-Methylaminopropyl)-9,10-dihydro-9,10-ethanoanthracene hydrochloride
9,10-Ethanoanthracene-9(10H)-propanamine, N-methyl-, hydrochloride
9,10-Ethanoanthracene-9(10H)-propylamine, N-methyl-, hydrochloride
AB0012620
AB2000619
AC-8249
AC1L2G8I
AC1Q38UP
AKOS015961872
AKOS015994755
Ambap10347-81-6
AN-8185
BA 34276
BB_SC-2110
BCP0726000234
BCP9000894
C-54992
C20H23N.HCl
CAS-10347-81-6
CCG-220346
CCG-38957
CHEBI:6691
CHEMBL1237135
Ciba 34276 Ba
CPD000148117
CS-2553
CTK8G0746
D00818
Deprilept
Deprilept;Ludiomil;Psymion
DSSTox_CID_24507
DSSTox_GSID_44507
DSSTox_RID_80277
DTXSID2044507
EINECS 233-758-8
EU-0100812
FT-0659758
HMS1569E13
HMS1920J13
HY-B0444
J-000980
KS-00001F7N
KS-5095
KSC-315-031-
KUC112481C
LP00812
LS-66339
Ludiomil
Ludiomil (TN)
Ludiomil HCl
M 9651
M2527
Maprotiline (hydrochloride)
Maprotiline Hcl
Maprotiline hydrochloride (JP17/USP)
Maprotiline hydrochloride [USAN:JAN]
Maprotiline hydrochloride [USP:JAN]
Maprotiline Hydrochloride 1.0 mg/ml in Methanol (as free base)
Maprotiline hydrochloride, >99% (HPLC), powder
Maprotiline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Maprotiline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Maprotiline, Ludiomil Hydrochloride
Maprotiline(hydrochloride)
Maprotilline HCl
methyl(3-{tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaen-1-yl}propyl)amine hydrochloride
methyl(3-{tetracyclo[6.6.2.0(2),.0,(1)]hexadeca-2,4,6,9,11,13-hexaen-1-yl}propyl)amine hydrochloride
MFCD00079464
MLS000069552
MLS000557000
MLS000758284
MLS001148189
MLS001423998
MolPort-000-826-653
MolPort-006-069-325
N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine hydrochloride
N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine hydrochloride
NC00056
NCGC00094145-01
NCGC00094145-02
NCGC00094145-03
NCGC00094145-04
NCGC00254894-01
NCGC00261497-01
NSC-757085
NSC757085
Opera_ID_1466
Opera_ID_513
Pharmakon1600-01500373
Prestwick_749
Psymion
REGID_for_CID_71478
s2517
SAM001246989
SC-26760
SCHEMBL121014
SMR000058834
SMR000148117
SPECTRUM1500373
Tox21_300992
Tox21_500812
UNII-7C8J54PVFI

US Patents and Regulatory Information for MAPROTILINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Am Therap MAPROTILINE HYDROCHLORIDE maprotiline hydrochloride TABLET;ORAL 072129-001 Jan 14, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs MAPROTILINE HYDROCHLORIDE maprotiline hydrochloride TABLET;ORAL 071943-001 Dec 30, 1987 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan MAPROTILINE HYDROCHLORIDE maprotiline hydrochloride TABLET;ORAL 072285-002 Oct 3, 1988 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs Teva MAPROTILINE HYDROCHLORIDE maprotiline hydrochloride TABLET;ORAL 072163-001 Jun 1, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
Harvard Business School
UBS
Johnson and Johnson
Cerilliant
Fuji
Express Scripts
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.